Pentosidine levels in nonproteinuric diabetes associated with both low estimated glomerular filtration rate and cataract

Diabetes, Metabolic Syndrome and Obesity

Volumn 5, Issue , 2012, Pages 155-164

  Lim, Xiu Li ^a   Teo, Boon Wee ^a   Tai, Bee Choo ^a   Wong, Tien Y ^b   Ng, Daniel P K ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

Author keywords

Advanced glycation endproducts; Chinese; Normoalbuminuria; Renal function

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIHYPERTENSIVE AGENT; GLYCOSYLATED HEMOGLOBIN; PENTOSIDINE; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD LEVEL; CARBOHYDRATE ANALYSIS; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; PENTOSIDINE BLOOD LEVEL; RISK FACTOR; SINGAPORE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84872285827     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/dmso.s32283     Document Type: Article

References (25)

1. Kramer CK, Leitão CB, Pinto LC, Silveiro SP, Gross JL, Canani LH. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 2007;30:1998-2000.
2. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: UKPDS 74. Diabetes. 2006;55: 1832-1839.
3. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27:195-200.
4. Tsalamandris C, Allen TJ, Gilbert RE., etal. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes. 1994;43:649-655.
5. An JH, Cho YM, Yu HG, etal. The clinical characteristics of normoalbuminuric renal insufficiency in Korean type 2 diabetic patients: a possible early stage renal complication. J Korean Med Sci. 2009;24 Suppl 1:S75-S81.
6. Yokoyama H, Sone H, Oishi M, etal. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management Study (JDDM15). Nephrol Dial Transplant. 2009;24:1212-1219.
7. Lu WN, Li H, Zheng FP, Huang H, Ruan Y. Renal insufficiency and its associated factors in type 2 diabetic patients with normoalbuminuria. Zhonghua Nei Ke Za Zhi. 2010;49:24-27. Chinese.
8. [No authors listed]. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-S266.
9. Hashimoto H, Arai K, Chikuda M, Obara Y. Relationship between pentosidine and pyridinoline levels in human diabetic cataract lenses. J Clin Biochem Nutr. 2010;47:233-237.
10. Franke S, Dawczynski J, Strobel J, Niwa T, Stahl P, Stein G. Increased levels of advanced glycation end products in human cataractous lenses. J Cataract Refract Surg. 2003;29:998-1004.
11. Saxena P, Saxena AK, Cui XL, Obrenovic M, Gudipaty K, Monnier VM. Transition metal-catalyzed oxidation of ascorbate in human cataract extracts: possible role of advanced glycation end products. Invest Ophthalmol Vis Sci. 2000;41:1473-1481.
12. Hashimoto H, Arai K, Yoshida S, Chikida M, Obara Y. Pentosidine and autofluorescence in lenses of diabetic patients. Jpn J Opthalmol. 1997;41:274-277.
13. Nagaraj RH, Sell DR, Prabhakaram M, Ortwerth BJ, Monnier VM. High correlation between pentosidine protein crosslinks and pigmentation implicates ascorbate oxidation in human lens senescence and cataractogenesis. Proc Natl Acad Sci U S A. 1991;88:10257-10261.
14. Lyons TJ, Silvestri G, Dunn JA, Dyer DG, Baynes JW. Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. Diabetes. 1991;40:1010-1015.
15. Furuya R, Kumagai H, Odamaki M, Takahashi M, Miyaki A, Hishida A. Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients. Nephron Clin Pract. 2009;112:255-261.
16. Calabrese V, Mancuso C, Sapienza M, etal. Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones. 2007;12:299-306.
17. Kato A, Odamaki M, Hishida A. Association between blood indoxyl sulfate and carbonyl stress marker in hemodialysis patients. Clin Nephrol. 2003;60:161-167.
18. Misselwitz J, Franke S, Kauf E, John U, Stein G. Advanced glycation end products in children with chronic renal failure and type 1 diabetes. Pediatr Nephrol. 2002;17:316-321.
19. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis. 2001;38(4 Suppl 1):S100-S106.
20. Miyata T, Ueda Y, Yamada Y, etal. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol. 1998;9: 2349-2356.
21. Sugiyama S, Miyata T, Ueda Y, etal. Plasma levels of pentosidine in diabetic patients: an advanced glycation endproduct. J Am Soc Nephrol. 1998;9:1681-1688.
22. Sugiyama S, Miyata T, Horie K, etal. Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant. 1996;11 Suppl 5: 91-94.
23. Beiran I, Scharf J, Tamir A, Miller B. Influence of systemic diseases and environmental factors on age at appearance, location and type of acquired cataract. Metab Pediatr Syst Ophthalmol. 1994;17:34-37.
24. Huynh SC, Kifley A, Strippoli GFM, Mitchell P. Is renal impairment a predictor of cataract or cataract surgery? Findings from a population-based study. Ophthalmology. 2005;112:293-300.
25. Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes. 2012;61:549-559.